Where Does Rocket Pharmaceuticals Inc. (RCKT) Rank When It Comes To Price-To-Earnings Ratio?


Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) finished Friday with an addition of $0.07 to close at $19.57, an upside of 0.36 percent. An average of 1,047,180 shares of common stock have been traded in the last five days. There was a gain of $0.37 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 1,226,415 shares traded, while the 50-day average volume stands at 937,888.

RCKT stock has increased by 3.65% in the last month. The company shares reached their 1-month lowest point of $16.85 on 12/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $7.57 and a high of $24.18 in 52 weeks. It has reached a new high 2 times so far this year and lost -10.35% or -$2.26 in price. In spite of this, the price is down -19.07% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

RCKT stock investors should be aware that Rocket Pharmaceuticals Inc. (RCKT) stock had its last reported insider trading activity 276 days ago on Oct 06.

Valuation Metrics

Rocket Pharmaceuticals Inc. (RCKT) stock’s beta is 1.43. Other valuation ratios to consider include the price-to-book (PB) ratio at 3.53.

Financial Health

The quick ratio of Rocket Pharmaceuticals Inc. for the three months ended September 29 was 10.30, and the current ratio was 10.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.05 and a total debt to equity ratio of 0.06 for the quarter ending September 29. Its gross profit as reported stood at $2.98 million compared to revenue of $167.25 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Rocket Pharmaceuticals Inc.’s return on assets was -44.20%.

Earnings Surprise

For the three-month period that ended September 29, Rocket Pharmaceuticals Inc. had $109.87 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$57.76 million in the quarter, while revenues of -$54.4 million were grew 13.23%. The analyst consensus anticipated Rocket Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.79 per share, but it turned out to be -$0.87, a -10.10% surprise. For the quarter, EBITDA amounted to -$58.47 million. Shareholders own equity worth $75.68 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Rocket Pharmaceuticals Inc. (RCKT) price momentum. RSI 9-day as of the close on 30 December was 49.70%, suggesting the stock is Neutral, with historical volatility in this time frame at 101.05%.

As of today, RCKT’s price is $18.59 +1.93% or $0.37 from its 5-day moving average. RCKT is currently trading +6.42% higher than its 20-day SMA and +20.58% higher than its 100-day SMA. However, the stock’s current price level is +16.49% above the SMA50 and +32.32% above the SMA200.

The stochastic %K and %D were 33.43% and 24.64%, respectively, and the average true range (ATR) was 1.62. With the 14-day stochastic at 41.03% and the average true range at 1.58, the RSI (14) stands at 50.63%. The stock has reached -0.56 on the 9-day MACD Oscillator while the 14-day reading was at -1.32.

Analyst Ratings

Canaccord Genuity launched coverage on Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) in its analyst report released on November 08, 2022. The firm assigned the stock a Buy rating.


Please enter your comment!
Please enter your name here